A detailed history of Great Point Partners LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Great Point Partners LLC holds 8,559,000 shares of UNCY stock, worth $5.91 Million. This represents 1.62% of its overall portfolio holdings.

Number of Shares
8,559,000
Holding current value
$5.91 Million
% of portfolio
1.62%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.24 - $0.54 $2.05 Million - $4.62 Million
8,559,000 New
8,559,000 $3.51 Million

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $10.4M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.